Literature DB >> 18292104

Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.

Patricia Woo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18292104     DOI： 10.1136/ard.2007.082859

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  [IL-1 antagonists].

Authors:  I Kötter; G Horneff
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

Review 3.  Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.

Authors:  Michael W Beresford
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

Review 4.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 5.  Systemic JIA: new developments in the understanding of the pathophysiology and therapy.

Authors:  Sebastiaan J Vastert; Wietse Kuis; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

Review 6.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 7.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

8.  Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study.

Authors:  Ebun Omoyinmi; Raja Hamaoui; Annette Bryant; Mike Chao Jiang; Trin Athigapanich; Despina Eleftheriou; Mike Hubank; Paul Brogan; Patricia Woo
Journal:  Pediatr Rheumatol Online J       Date:  2016-02-09       Impact factor: 3.054

9.  Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Authors:  Claudia Kedor; Joachim Listing; Jan Zernicke; Anja Weiß; Frank Behrens; Norbert Blank; Joerg Christoph Henes; Joern Kekow; Andrea Rubbert-Roth; Hendrik Schulze-Koops; Eva Seipelt; Christof Specker; Eugen Feist
Journal:  Ann Rheum Dis       Date:  2020-05-13       Impact factor: 27.973
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.